查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864381

慢性脫髓鞘多發性神經炎市場依治療方法、最終用戶、通路、患者年齡和疾病嚴重程度分類－2025-2032年全球預測

Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment Modality, End User, Distribution Channel, Patient Age, Disease Severity - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，慢性脫髓鞘多發性神經炎(CIDP) 市場將成長至 39.6 億美元，複合年成長率為 5.98%。

關鍵市場統計數據
基準年 2024 24.9億美元
預計年份：2025年 26.4億美元
預測年份 2032 39.6億美元
複合年成長率 (%) 5.98%

簡潔明了地梳理臨床複雜性、治療路徑和策略重點，為相關人員在醫療、研究和商業化方面做出明智的決策提供指導。

慢性脫髓鞘多發性神經炎在臨床、診斷和治療方面具有獨特的複雜性，需要綜合分析以製定策略決策。本執行摘要整合了關於疾病生物學、診療路徑、治療方法和商業環境的最新知識，為臨床醫生、支付方和行業相關人員提供簡潔而全面的概述。它探討了不斷發展的診斷標準、免疫療法的進展以及醫療服務模式的改變如何相互作用，從而影響患者預後和服務使用。

本報告著重關注循證治療實踐和醫療機構的實際運作情況，將臨床終點與治療耐受性、輸液基礎設施以及專科診所和居家醫療服務的容量等現實因素聯繫起來。此外，引言部分概述了正在重塑競爭格局的新興臨床試驗趨勢和監管方法。最後，本部分為深入探討變革性變化及其對收費系統、市場區隔資訊、區域趨勢的影響，以及為負責駕馭複雜且快速變化領域的管理人員和臨床領導者提供的實用建議奠定了基礎。

診斷技術進步、治療方法創新和醫療服務體系重塑如何融合，從而重新定義患者管理中的治療方法和價值評估

慢性脫髓鞘多發性神經炎的治療管理格局正經歷著一場變革，其驅動力包括技術的成熟、監管的完善以及患者期望的改變。新型診斷方法和生物標記研究的進展正在改善病例識別和預後分層，從而支持更具針對性的治療策略。同時，免疫球蛋白療法製劑和給藥方式的進步，以及對單株抗體和其他免疫調節劑認知的不斷加深，正在拓展臨床醫生的選擇範圍，並促使人們重新評估長期治療通訊協定。

此外，醫療系統正在調整服務模式，在臨床上適宜的情況下，更加重視門診和居家治療。這一轉變得益於皮下注射免疫球蛋白製劑和遠端監測技術的進步，從而減少了對住院輸液中心的依賴，並提高了患者的便利性。這一轉變的趨勢還包括支付者對長期治療價值的審查，促使人們更加嚴格地評估療效並管理醫療資源。這些因素正在加速向個人化、價值導向醫療保健的轉變，這種醫療保健模式既重視臨床療效，也注重系統的永續性。

評估關稅政策對供應鏈、生產策略和治療藥物可近性的影響，以及其對採購和臨床決策的意義

貿易和關稅政策的發展可能對用於治療慢性脫髓鞘多發性神經炎(CIDP) 的療法的生產經濟性、供應鏈韌性和成本結構產生重大影響。原料和成品生技藥品的進口關稅和監管要求的變化可能會使上游採購流程複雜化，並促使製造商重新評估其供應商網路和庫存策略。同時，關稅可能會改變生產的地域經濟格局，促使製造商轉移製造地或採取雙重採購安排，以降低貿易中斷的風險。

這些發展也可能對相關人員產生後續影響。醫院藥局、專科診所和分銷管道可能面臨採購前置作業時間和價格壓力的變化，需要對合約和庫存管理進行調整。臨床醫生和醫療系統可能會遇到產品供應波動，這可能會影響多種靜脈注射和皮下給藥方式的治療選擇。因此，策略規劃應納入情境分析，評估關稅對供應連續性、產品成本以及居家照護和中心給藥的營運可行性的影響。同時，各機構應與支付方合作，制定符合新成本結構的報銷模式。

將治療特徵、護理環境、通路、年齡層和嚴重程度階段與臨床和營運決策框架聯繫起來的詳細細分分析

細分市場分析揭示了關鍵的營運和臨床挑戰，這些挑戰因治療方法、護理環境、分發機制、患者年齡層和疾病嚴重程度而異。就治療方法而言，治療組合包括皮質類固醇、免疫抑制劑（如硫唑嘌呤、Azathioprine、Mycophenolate Mofetil和Rituximab）、靜脈注射免疫球蛋白、血漿置換和皮下注射免疫球蛋白，每種方案的劑量要求、監測需求和安全性特徵各不相同，這些都會影響治療中心的選擇和資源分配。在此背景下，不同的免疫抑制劑亞型可能需要專門的監測通訊協定和病患諮詢，這可能會影響專科診所與綜合醫院的用藥模式。

終端使用者人口統計資料細分，可以凸顯居家醫療、醫院和專科診所之間在營運方面的權衡取捨。居家醫療模式優先考慮患者教育、設備相容性和遠端監測，而醫院則專注於輸液和急診護理能力。專科診所通常是確診和啟動長期免疫療法的中心，而醫院、線上藥房和零售藥房之間通路的差異會影響配藥方式、低溫運輸管理和患者就醫途徑。將患者年齡分為成人、老年人和兒童，可以揭示在安全考量、給藥策略和看護者支持需求方面的差異，這些都必須納入治療方案中。依疾病嚴重程度（輕度、中度、重度）進行細分，可以進一步明確治療順序、干預頻率和監測強度，從而影響決策路徑，而這些路徑又與支付方核准和護理協調要求密切相關。

全球主要區域的比較動態和策略考量正在影響治療方案的取得、報銷和提供方式。

區域趨勢正在影響美洲、歐洲、中東和非洲以及亞太市場的臨床實踐模式、法規環境、報銷框架和供應物流。在美洲，不斷發展的支付模式和強大的專科醫療網路支援重點關注門診輸液服務和臨床適宜的家庭給藥。同時，生物製藥和免疫療法監管規定的日益明確正在推動給藥平台的創新。相反，歐洲、中東和非洲某些地區在藥物取得和報銷方面的差異，需要製定區域策略，考慮國家藥品目錄、集中採購和區域生產夥伴關係。

在亞太地區，醫療基礎設施的快速發展和專科醫生數量的不斷成長，為更多人獲得先進療法創造了機會。然而，監管路徑和本地生產能力的差異仍然是挑戰。在這些全部區域，以價值為導向的採購模式的轉變以及對真實世界證據的日益重視，正在影響藥物目錄的製定和臨床指南的編寫。因此，新參與企業和現有供應商必須根據當地的監管、支付方和供應實際情況調整其商業化策略，同時協調其在整個地區的供應鏈和醫學事務工作，以確保醫療服務的一致性。

持續成長需要製造商和服務提供者既競爭又合作，以協調臨床證據、供應鏈物流和患者支援。

競爭資訊顯示，活躍於該治療領域的機構類型多樣，從生產免疫球蛋白療法的生物製藥企業到提供血漿置換和家庭輸液服務的專業服務供應商，不一而足。擁有臨床開發專長和完善的生產及分銷基礎設施的公司，能夠更好地應對生物製藥固有的複雜低溫運輸和品管要求。此外，投資於病患援助計畫、居家照護護理師培訓和數位化藥物管理工具的營業單位，能夠增強其對支付方和醫療服務提供者的價值提案。

製藥公司與物流供應商之間的合作，以及與學術機構合作進行上市後證據生成工作，正變得越來越普遍。這些合作有助於制定生命週期管理策略，並有助於產生支付方日益需要的真實世界資料。能夠提供可擴展輸注能力和簡化事前核准支持的服務供應商，正受到希望最大限度減少行政負擔的臨床醫生的青睞。總體而言，隨著治療模式的演變，那些將臨床證據產生與卓越營運和相關人員參與相結合的機構，更有可能保持競爭優勢。

為經營團隊提供實際的策略行動，以增強證據產生、強化供應鏈並推動醫療服務，從而實現持續的臨床和商業性成功。

為了最大限度地提高治療效果和營運永續性，產業領導者應採取多管齊下的策略，整合臨床證據開發、供應鏈韌性和相關人員參與。首先，應優先產生可靠的真實世界證據和有針對性的臨床研究，闡明長期療效、不同治療方法的療效比較以及能夠解決支付方顧慮的成本效益指標。其次，應透過多元化關鍵原料採購、建立區域性生產或填充包裝能力以及協商靈活的物流安排來降低關稅和貿易風險，從而增強供應鏈韌性。

第三，我們將投資醫療服務創新，透過培訓、遠端醫療整合和數位監測工具，擴大安全居家管理範圍並支持專科診所，從而提高患者的用藥依從性並降低醫療總成本。第四，我們將利用療效數據和病患報告指標，積極與支付者和政策制定者溝通，推動與臨床價值相符的報銷途徑。最後，我們將建立跨部門夥伴關係，包括與學術機構和患者權益倡導組織合作，以促進指南的採納、加強患者教育並確保不同年齡層和病情嚴重程度的患者都能公平地獲得醫療服務。這些努力將共同建構一個基於臨床信譽和營運適應性的穩健商業模式。

一種透明、多方面的研究途徑，結合專家訪談、系統文獻綜述和迭代檢驗，以產生可操作的臨床和營運見解。

本分析的調查方法結合了定性專家訪談、對原始文獻的嚴格審查以及對營運和監管趨勢的系統性綜合分析。關鍵投入包括與臨床專家、藥房部門負責人和醫療系統管理人員的諮詢，以了解當地對治療選擇、輸液能力和患者管理的觀點。這些訪談輔以對同行評審的臨床研究、監管指南和專業學會建議的系統性審查，以確保治療和診斷趨勢是基於檢驗的證據。

為確保可靠性，我們採用了多方資訊來源三角驗證法，並透過迭代式同儕審查進行檢驗。我們謹慎區分了既定的臨床實踐和新興的實驗方法，並識別出需要進一步研究的證據缺口。我們承認以下限制：臨床指引的區域差異和真實世界數據的定性差異可能會限制某些操作推論的普遍適用性。然而，我們的調查方法強調透明度、可重複性和對臨床、商業和政策決策者的實際應用性。

整合臨床趨勢、營運挑戰和策略優勢，以製定改善患者療效和永續醫療服務的路徑。

本執行摘要綜合分析了影響慢性脫髓鞘多發性神經炎治療的臨床、運作和策略因素。摘要重點闡述了向個人化免疫調節策略的轉變、對居家和門診治療模式的重視，以及真實世界證據在支持支付方參與方面日益成長的重要性。此外，分析還強調了可能影響治療方法可及性和選擇的供應鏈因素和政策主導壓力，並重申了相關人員之間積極進行緊急時應對計畫和協作的必要性。

總之，有效的應對措施需要在證據收集、物資管理和支付方合作方面採取協調一致的行動，以確保患者及時獲得適當的治療，同時使醫療系統能夠有效控制成本和提升服務能力。將臨床見解與切實可行的營運策略相結合的相關人員，將更有能力應對不確定性，並將科學進步轉化為改善慢性神經系統疾病患者預後的成果。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 透過推廣新一代皮下注射免疫球蛋白製劑，提高患者依從性和便利性
  • 開發新型FcRn受體抑制劑，以實現CIDP患者的持續疾病緩解。
  • 整合遠距神經病學平台，用於遠端監測和管理慢性發炎性脫髓鞘性多發性神經病變（CIDP）症狀
  • 預測性生物標記組合的進展將為CIDP管理中的個人化治療策略提供支持
  • 患者報告結局指標在指南真實世界中慢性發炎性脫髓鞘多發性神經病變（CIDP）治療方案調整方面正受到越來越多的關注。
  • 對影響CIDP保險覆蓋決策的長期免疫療法方案進行經濟評估
  • 一種針對難治性CIDP病例中髓鞘修復機制的新型基因治療方法
  • 引入多學科診療路徑以降低重度CIDP急性發作期間的住院率

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章慢性脫髓鞘多發性神經炎市場（依治療方式分類）

  • 皮質類固醇
  • 免疫抑制劑
    • Azathioprine
    • Cyclophosphamide
    • Mycophenolate Mofetil
    • Rituximab
  • 靜脈注射免疫球蛋白
  • 血漿置換
  • 皮下注射免疫球蛋白

第9章慢性脫髓鞘多發性神經炎市場（依最終用戶分類）

  • 居家醫療
  • 醫院
  • 專科診所

第10章慢性脫髓鞘多發性神經炎市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章慢性脫髓鞘多發性神經炎市場（依患者年齡分類）

  • 成人版
  • 老年人
  • 孩子們

第12章慢性脫髓鞘多發性神經炎市場（依疾病嚴重程度分類）

  • 溫和的
  • 緩和
  • 嚴重

第13章慢性脫髓鞘多發性神經炎市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章慢性脫髓鞘多發性神經炎市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國慢性脫髓鞘多發性神經炎市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Grifols, SA
    • CSL Behring AG
    • Octapharma AG
    • Takeda Pharmaceutical Company Limited
    • Baxter International Inc.
    • LFB SA
    • Kedrion SpA
    • Biotest AG
    • Kamada Ltd.
    • Shanghai RAAS Blood Products Co., Ltd.
Product Code: MRR-F97DD5A7D581

The Chronic Inflammatory Demyelinating Polyneuropathy Market is projected to grow by USD 3.96 billion at a CAGR of 5.98% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.49 billion
Estimated Year [2025] USD 2.64 billion
Forecast Year [2032] USD 3.96 billion
CAGR (%) 5.98%

Concise framing of clinical complexity, treatment pathways, and strategic priorities to orient stakeholders toward informed decisions across care, research, and commercialization

Chronic inflammatory demyelinating polyneuropathy presents distinct clinical, diagnostic, and therapeutic complexities that demand integrated analysis for strategic decision making. This executive summary synthesizes current understanding of disease biology, care pathways, therapeutic modalities, and the commercial environment to equip clinicians, payers, and industry stakeholders with a concise yet comprehensive briefing. It addresses how evolving diagnostic criteria, advances in immunotherapy, and shifts in care delivery intersect to influence patient journeys and service utilization.

By focusing on evidence-based treatment practices and operational realities across settings of care, the narrative connects clinical endpoints with real-world considerations such as treatment tolerability, infusion infrastructure, and the capacity of specialty clinics and home care services. Moreover, the introduction frames emerging clinical trial trends and regulatory approaches that are reshaping the competitive landscape. Ultimately, this section sets the stage for a deeper exploration of transformative shifts, tariff implications, segmentation intelligence, regional dynamics, and actionable recommendations crafted for executives and clinical leaders tasked with navigating a complex, rapidly changing field.

How diagnostic advances, treatment innovation, and care delivery redesign are converging to redefine therapeutic approaches and value assessment in patient management

The landscape for managing chronic inflammatory demyelinating polyneuropathy is undergoing transformative shifts driven by technological maturation, regulatory refinement, and evolving patient expectations. Novel diagnostics and biomarker research are improving case ascertainment and prognostic stratification, which in turn support more targeted therapeutic strategies. Concurrently, advances in the formulation and delivery of immunoglobulin therapies, alongside growing experience with monoclonal antibodies and other immunomodulatory agents, are expanding clinician options and prompting reassessment of long-term management protocols.

At the same time, health systems are adjusting care delivery models to emphasize outpatient and home-based administration where clinically appropriate. This shift is facilitated by advancements in subcutaneous immunoglobulin formulations and remote monitoring technologies, which reduce reliance on inpatient infusion centers and enhance patient convenience. Transitional dynamics also include payer scrutiny around long-term therapy value, leading to more rigorous outcomes measurement and utilization management. Collectively, these forces are accelerating a move toward personalized, value-oriented care that recognizes both clinical efficacy and system sustainability.

Assessment of tariff policy effects on supply chains, manufacturing strategies, and treatment availability with implications for procurement and clinical decision making

Policy developments in trade and tariffs can exert significant influence on manufacturing economics, supply chain resilience, and the cost structure of therapies used in chronic inflammatory demyelinating polyneuropathy care. Changes to import duties or regulatory requirements for raw materials and finished biologics may increase upstream sourcing complexity, prompting manufacturers to reassess supplier networks and inventory strategies. In parallel, tariffs can shift the geographic economics of production, encouraging relocation of manufacturing nodes or the adoption of dual-sourcing arrangements to mitigate exposure to trade disruptions.

These dynamics can cascade into downstream stakeholders: hospital pharmacies, specialty clinics, and distribution channels may face altered procurement lead times or pricing pressures that necessitate adjustments in contracting and inventory management. Clinicians and health systems may experience variability in product availability, which could influence therapeutic choices between intravenous and subcutaneous formulations where multiple options exist. Consequently, strategic planning must incorporate scenario analysis of tariff impacts on supply continuity, cost of goods, and the operational feasibility of home care versus facility-based administration, while also engaging with payers to align reimbursement models with emerging cost structures.

In-depth segmentation analysis linking therapy characteristics, care settings, distribution pathways, age cohorts, and severity gradations to clinical and operational decision frameworks

Segment-specific analysis reveals differentiated operational and clinical imperatives across treatment modalities, care settings, distribution mechanisms, patient age groups, and disease severity categories. When examined by treatment modality, the therapeutic mix spans corticosteroids, immunosuppressants - including azathioprine, cyclophosphamide, mycophenolate mofetil, and rituximab - intravenous immunoglobulin, plasma exchange, and subcutaneous immunoglobulin, each with distinct administration requirements, monitoring needs, and safety profiles that influence site selection and resource allocation. In this context, immunosuppressant subtypes demand specialized monitoring protocols and patient counseling that can shape utilization patterns in specialty clinics compared with broader hospital settings.

End-user segmentation highlights the operational tradeoffs between home care, hospitals, and specialty clinics. Home care models prioritize patient education, device compatibility, and remote monitoring, while hospitals underscore infusion capacity and acute management capabilities. Specialty clinics often serve as hubs for diagnostic clarification and initiation of long-term immunotherapy. Distribution channel differentiation across hospital pharmacy, online pharmacy, and retail pharmacy affects dispensing practices, cold chain stewardship, and patient access. Patient age segmentation into adult, geriatric, and pediatric populations underscores differing safety considerations, dosing strategies, and caregiver support needs that must be integrated into treatment planning. Disease severity segmentation - mild, moderate, and severe - further informs therapeutic sequencing, frequency of interventions, and intensity of monitoring, creating decision pathways that intersect with payer authorization and care coordination requirements.

Comparative regional dynamics and strategic considerations across major global territories shaping access, reimbursement, and delivery of therapeutic options

Regional dynamics shape clinical practice patterns, regulatory environments, reimbursement frameworks, and supply logistics across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, evolving payer models and robust specialty care networks support a focus on outpatient infusion services and home administration where clinically appropriate, while regulatory clarity around biologics and immunotherapies encourages innovation in delivery platforms. Conversely, certain jurisdictions in Europe, the Middle East, and Africa exhibit heterogeneity in access and reimbursement, prompting localized strategies that account for national formularies, centralized procurement, and regional manufacturing partnerships.

In the Asia-Pacific region, rapid growth in healthcare infrastructure and an expanding base of specialist clinicians are creating opportunities for broader access to advanced therapies, though variability in regulatory pathways and local manufacturing capacity remains a factor. Across these regions, transitions toward value-based procurement and a greater emphasis on real-world evidence are influencing formulary decisions and clinical guidelines. Therefore, market entrants and established suppliers must calibrate commercialization strategies to local regulatory, payer, and delivery realities, while also coordinating cross-regional supply chain and medical affairs efforts to ensure consistent standards of care.

Competitive and collaborative imperatives for manufacturers and service providers to align clinical evidence, supply logistics, and patient support for sustainable growth

Competitive intelligence indicates that a diverse set of organizations - from biopharmaceutical manufacturers producing immunoglobulin formulations to specialty service providers delivering plasma exchange and home infusion capabilities - are active in this therapeutic area. Firms that combine clinical development expertise with robust manufacturing and distribution infrastructures are better positioned to meet the complex cold chain and quality control demands inherent to biologic therapies. In addition, entities that invest in patient support programs, training for home care nurses, and digital adherence tools strengthen their value proposition to payers and providers.

Partnerships between pharmaceutical companies and logistics providers, as well as collaborations with academic centers for post-marketing evidence generation, are becoming more common. These alliances support lifecycle management strategies and help build the real-world datasets that payers increasingly require. Service providers that offer scalable infusion capacity and streamlined prior authorization support gain traction with clinicians seeking to minimize administrative burden. Overall, organizations that align clinical evidence generation with operational excellence and stakeholder engagement are likely to sustain competitive advantage as treatment paradigms evolve.

Practical strategic measures for executives to enhance evidence generation, fortify supply chains, and advance care delivery to sustain clinical and commercial success

Industry leaders should pursue a multipronged strategy that integrates clinical evidence development, supply chain resilience, and stakeholder engagement to maximize therapeutic impact and operational sustainability. First, prioritize generation of robust real-world evidence and targeted clinical studies that clarify long-term outcomes, comparative effectiveness across modalities, and cost-utility measures that resonate with payers. Second, strengthen supply chain resilience by diversifying sourcing of critical raw materials, establishing regional manufacturing or fill-finish capabilities, and negotiating flexible logistics arrangements to mitigate tariff and trade risks.

Third, invest in care delivery innovations that expand safe home administration and support specialty clinics through training, telehealth integration, and digital monitoring tools to improve adherence and reduce total cost of care. Fourth, engage proactively with payers and policy makers to align reimbursement pathways with clinical value, leveraging outcomes data and patient-reported measures. Finally, cultivate cross-sector partnerships - including with academic institutions and patient advocacy groups - to accelerate guideline adoption, improve patient education, and ensure equitable access across age cohorts and severity profiles. Together, these actions create a resilient commercial model grounded in clinical credibility and operational adaptability.

Transparent, multi-source research approach combining expert interviews, systematic literature review, and iterative validation to produce actionable clinical and operational insights

The research methodology underpinning this analysis combines qualitative expert engagement, rigorous review of primary literature, and structured synthesis of operational and regulatory developments. Primary inputs included consultations with clinical specialists, pharmacy leaders, and health system administrators to capture frontline perspectives on treatment selection, infusion capacity, and patient management. These interviews were complemented by a systematic review of peer-reviewed clinical studies, regulatory guidance, and professional society recommendations to ensure that therapeutic and diagnostic trends are grounded in validated evidence.

To ensure reliability, findings were triangulated across multiple sources and validated through iterative expert review. Attention was given to distinguishing established clinical practice from emerging experimental approaches, and to identifying gaps in evidence where further research is warranted. Limitations are acknowledged: regional heterogeneity in clinical guidelines and the variable quality of real-world datasets can constrain the generalizability of certain operational inferences. Nonetheless, the methodology emphasizes transparency, reproducibility, and the practical applicability of insights for decision-makers in clinical, commercial, and policy roles.

Synthesis of clinical trends, operational challenges, and strategic levers that together define the pathway to improved patient outcomes and sustainable care delivery

This executive synthesis delivers a cohesive view of the clinical, operational, and strategic forces shaping care for chronic inflammatory demyelinating polyneuropathy. It underscores a shift toward personalized immunomodulatory strategies, increasing emphasis on home and outpatient delivery models, and the rising importance of real-world evidence to support payer engagement. The analysis also highlights supply chain considerations and policy-driven pressures that can influence availability and selection of therapies, reinforcing the need for proactive contingency planning and stakeholder alignment.

In closing, effective responses require coordinated action across evidence generation, supply operations, and payer engagement to ensure that patients receive timely, appropriate care while health systems manage cost and capacity. Stakeholders who integrate clinical insight with pragmatic operational strategies will be better positioned to navigate uncertainty and to translate scientific advances into improved outcomes for patients living with this chronic neurologic condition.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of next-generation subcutaneous immunoglobulin formulations improving patient adherence and convenience
  • 5.2. Development of novel FcRn receptor inhibitors for sustained disease remission in CIDP patients
  • 5.3. Integration of tele-neurology platforms for remote monitoring and management of chronic CIDP symptoms
  • 5.4. Advances in predictive biomarker panels enabling personalized treatment strategies for CIDP management
  • 5.5. Rising focus on patient-reported outcome measures to guide therapy adjustments in real-world CIDP care
  • 5.6. Economic evaluations of long-term immunotherapy regimens influencing payer coverage decisions in CIDP
  • 5.7. Emerging gene therapy approaches targeting myelin repair mechanisms in refractory CIDP cases
  • 5.8. Implementation of multidisciplinary care pathways reducing hospitalization rates for severe CIDP exacerbations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment Modality

  • 8.1. Corticosteroids
  • 8.2. Immunosuppressants
    • 8.2.1. Azathioprine
    • 8.2.2. Cyclophosphamide
    • 8.2.3. Mycophenolate Mofetil
    • 8.2.4. Rituximab
  • 8.3. Intravenous Immunoglobulin
  • 8.4. Plasma Exchange
  • 8.5. Subcutaneous Immunoglobulin

9. Chronic Inflammatory Demyelinating Polyneuropathy Market, by End User

  • 9.1. Home Care
  • 9.2. Hospitals
  • 9.3. Specialty Clinics

10. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Patient Age

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Disease Severity

  • 12.1. Mild
  • 12.2. Moderate
  • 12.3. Severe

13. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Grifols, S.A.
    • 16.3.2. CSL Behring AG
    • 16.3.3. Octapharma AG
    • 16.3.4. Takeda Pharmaceutical Company Limited
    • 16.3.5. Baxter International Inc.
    • 16.3.6. LFB S.A.
    • 16.3.7. Kedrion S.p.A.
    • 16.3.8. Biotest AG
    • 16.3.9. Kamada Ltd.
    • 16.3.10. Shanghai RAAS Blood Products Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYE